A Randomized Trial for Patients With High-Grade Myeloid Neoplasms With Measurable Residual Disease (MRD): CPX-351 vs. Immediate Allogeneic Hematopoietic Cell Transplantation
Latest Information Update: 27 May 2024
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 31 Aug 2023 Status changed from active, no longer recruiting to discontinued.
- 06 Jul 2023 Planned End Date changed from 6 Aug 2023 to 27 Aug 2023.
- 06 Jul 2023 Planned primary completion date changed from 6 Aug 2023 to 27 Aug 2023.